| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1995;25:92-97.)
© 1995 American Heart Association, Inc.
Articles |
Ramipril-Induced Regression of Left Ventricular Hypertrophy in Treated Hypertensive Individuals
From the HYCAR Study Group. See "Acknowledgments" for a complete listing of participants.
Abstract The objective of this trial was to assess the effects of 6-month daily treatment with two doses of ramipril on left ventricular mass and the dependence of this on blood pressure changes in hypertensive patients with left ventricular hypertrophy. After a selection phase of 4 to 6 weeks with patients under antihypertensive therapy with 20 mg furosemide daily, 115 patients with either controlled or uncontrolled hypertension and left ventricular hypertrophy were randomized in a double-blind manner to receive either placebo (n=40), 1.25 mg (low dose, n=38), or 5 mg (regular dose, n=37) ramipril daily for 6 months. Treatment with furosemide was continued unchanged during this phase. The main outcome measured was left ventricular hypertrophy regression as assessed from central blind reading of echocardiograms recorded at randomization and after 6 months. No significant differences were observed for changes in casual or ambulatory blood pressure between the three groups. Left ventricular mass index was found to be significantly reduced in patients receiving 5 mg ramipril compared with those receiving placebo (-10.8±3.7 versus +4.1±4.0 g/m2, P=.008); in patients receiving 1.25 mg ramipril, the difference was close to borderline significance compared with placebo (-7.0±4.3 g/m2, P=.06). Similar results were observed for changes in left ventricular mass (-20.3±6.6 and -13.0±7.8 g in the 5- and 1.25-mg ramipril groups, respectively, versus +9.1±7.2 g in the placebo group; P=.004 and .04, respectively). In a multiple regression model testing 10 potential explicative variables, we found that this reduction was correlated with treatment, both 1.25 and 5.0 mg ramipril (P=.03 and .01, respectively), and with the baseline value of the left ventricular mass index (P=.005). Changes in ambulatory or casual systolic and diastolic blood pressures were not predictive of changes in left ventricular mass (P=.15 and .16, respectively). Ramipril at 1.25 and 5 mg daily for 6 months can induce left ventricular hypertrophy regression, independent of changes in blood pressure, in patients under furosemide (20 mg/d) antihypertensive therapy. The implications of this regression for cardiovascular morbidity and mortality in hypertensive patients should now be assessed.
Key Words: clinical trials • hypertrophy, left ventricular • hypertension, essential • angiotensin-converting enzyme inhibitors
This article has been cited by other articles:
 |
|
 |
|
  M. Marre, M. Lievre, G. Chatellier, J. F E Mann, P. Passa, and J. Menard Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ, February 28, 2004; 328(7438): 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G Friedrich, B. Dahlof, U. Sechtem, T. Unger, M. Knecht, R. Dietz, and TELMAR Investigators Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension -- a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months -- rationale and study design Journal of Renin-Angiotensin-Aldosterone System, December 1, 2003; 4(4): 234 - 243. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Myerson, H. E. Montgomery, M. J. World, and D. J. Pennell Left Ventricular Mass: Reliability of M-Mode and 2-Dimensional Echocardiographic Formulas Hypertension, November 1, 2002; 40(5): 673 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Nichols, B. Schuler, M. F. O'Rourke, J. Mathew, P. Sleight, E. Lonn, Q. Yi, J. Pogue, J. Bosch, S. Yusuf, et al. Ramipril and Cardiovascular Risk Reduction * Response Circulation, June 25, 2002; 105 (25): e194 - e195. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Myerson, N. G. Bellenger, and D. J. Pennell Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance Hypertension, March 1, 2002; 39(3): 750 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, A. Reddert, S. Wassmann, K. Strehlow, M. Bohm, and G. Nickenig Insulin-like growth factor induces up-regulation of AT1-receptor gene expression in vascular smooth muscle cells Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 273 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Willenheimer, E. Rydberg, L. Oberg, S. Juul-Moller, and L. Erhardt ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function Eur. Heart J., November 2, 1999; 20(22): 1647 - 1656. [Abstract] [PDF]
|
|
|
|
|
|
T. Ogawa, W. Linz, M. Stevenson, B. G. Bruneau, M. L. Kuroski de Bold, J. H. Chen, H. Eid, B. A. Scholkens, and A. J. de Bold Evidence for Load-Dependent and Load-Independent Determinants of Cardiac Natriuretic Peptide Production Circulation, June 1, 1996; 93(11): 2059 - 2067. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. E. Schmieder, P. Martus, and A. Klingbeil Reversal of Left Ventricular Hypertrophy in Essential Hypertension: A Meta-analysis of Randomized Double-blind Studies JAMA, May 15, 1996; 275(19): 1507 - 1513. [Abstract] [PDF]
|
|